Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

Vaccine

Volumn 27, Issue 33, 2009, Pages 4412-4423

  Sun, Ronggai ^a   Skeiky, Yasir A W ^a   Izzo, Angelo ^b   Dheenadhayalan, Veerabadran ^a   Imam, Zakaria ^a   Penn, Erica ^a   Stagliano, Katherine ^a   Haddock, Scott ^a   Mueller, Stefanie ^a   Fulkerson, John ^a   Scanga, Charles ^a   Grover, Ajay ^b   Derrick, Steven C ^c   Morris, Sheldon ^c   Hone, David M ^a   Horwitz, Marcus A ^e   Kaufmann, Stefan H E ^d   Sadoff, Jerald C ^a  

^a Aeras Global TB Vaccine Foundation   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ad35; Antigen over expression; Endosome lysis; Prime boost; Protection; Recombinant BCG; T cell; Tuberculosis; Vaccination

Indexed keywords

ANTIGEN; BCG VACCINE; CLOSTRIDIUM PERFRINGENS TOXIN; CYTOLYSIN; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DRUG SAFETY; ENDOSOME; FEMALE; GENOME; GUINEA PIG; IMMUNE RESPONSE; LYSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SCID MOUSE; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BCG VACCINE; CELL LINE; ERYTHROCYTES; FEMALE; GENES, BACTERIAL; GUINEA PIGS; HEMOLYSIN PROTEINS; HEMOLYSIS; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; SHEEP; TUBERCULOSIS;

EID: 67649321241     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.048     Document Type: Article

References (74)

1. Al-Attiyah R., Mustafa A.S., Abal A.T., El-Shamy A.S., Dalemans W., and Skeiky Y.A. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 138 (2004) 139-144
2. Allen S.S., and McMurray D.N. Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs. Infect Immun 71 (2003) 4271-4277
3. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 (1994) 2536-2544
4. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
5. Anon. Tuberculosis: a global emergency. World Health Forum 14 (1993) 438
6. Anon. WHO and UNAIDS call for joint HIV-tuberculosis action. Bull World Health Organ 82 (2004) 810
7. Anon. WHO declares tuberculosis a global emergency. Soz Praventivmed 38 (1993) 251-252
8. Aziz M.A., and Wright A. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis 41 Suppl. 4 (2005) S258-262
9. Bosma M.J., and Carroll A.M. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9 (1991) 323-350
10. Boyton R.J. Infectious lung complications in patients with HIV/AIDS. Curr Opin Pulm Med 11 (2005) 203-207
11. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104 (2007) 5596-5601
12. Cai H., Yu D.H., Hu X.D., Li S.X., and Zhu Y.X. A combined DNA vaccine-prime. BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol 25 (2006) 438-447
13. Chadha V.K. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis 9 (2005) 1072-1082
14. Chintu C., and Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis 9 (2005) 477-484
15. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
16. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994) 698-702
17. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 (1993) 2243-2247
18. Delogu G., Li A., Repique C., Collins F., and Morris S.L. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 70 (2002) 292-302
19. Derrick S.C., Repique C., Snoy P., Yang A.L., and Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 72 (2004) 1685-1692
20. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174 (2005) 6332-6339
21. Dolin P.J., Raviglione M.C., and Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 72 (1994) 213-220
22. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 (2005) 2767-2775
23. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programs. World Health Organization, vol. WHO/V&B/99.23. 1999.
24. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993) 2249-2254
25. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 89 (1992) 12013-12017
26. Forster M.J., Morris P., and Sohal R.S. Genotype and age influence the effect of caloric intake on mortality in mice. FASEB J 17 (2003) 690-692
27. Geluk A., van Meijgaarden K.E., Franken K.L., Drijfhout J.W., D'Souza S., Necker A., et al. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol 165 (2000) 6463-6471
28. Glynn J.R., Whiteley J., Bifani P.J., Kremer K., and van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 8 (2002) 843-849
29. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Eddine A.N., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
30. Havlir D.V., and Barnes P.F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340 (1999) 367-373
31. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., and Kaufmann S.H. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 95 (1998) 5299-5304
32. Hinchey J., Lee S., Jeon B.Y., Basaraba R.J., Venkataswamy M.M., Chen B., et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117 (2007) 2279-2288
33. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198 (2008) 1491-1501
34. Hopewell P., Cynamon M., Starke J., Iseman M., and O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 15 Suppl. 1 (1992) S296-S306
35. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 (2003) 1672-1679
36. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 73 (2005) 4676-4683
37. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000) 13853-13858
38. Horwitz M.A., Lee B.W., Dillon B.J., and Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 92 (1995) 1530-1534
39. Jones S., Preiter K., and Portnoy D.A. Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen. Mol Microbiol 21 (1996) 1219-1225
40. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.F., Newport M., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 335 (1996) 1956-1961
41. Jouanguy E., Lamhamedi-Cherradi S., Lammas D., Dorman S.E., Fondaneche M.C., Dupuis S., et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 21 (1999) 370-378
42. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 (2005) 3753-3761
43. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 (2001) 20-30
44. Korf J., Stoltz A., Verschoor J., De Baetselier P., and Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur J Immunol 35 (2005) 890-900
45. Laal S., and Skeiky Y.A.W. Immune-based methods. In: Cole S.T., Eisenach K.D., McCurray D.N., and Jacobs W.R. (Eds). Tuberculosis and the tubercle bacillus (2005), ASM Press, Washinton, DC 71-83
46. Langermans J.A., Doherty T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
47. Lugosi L., Jacobs W., and Bloom B.R. Transformation of BCG with plasmid DNA. Acta Leprol 7 Suppl. 1 (1989) 256-257
48. Maher D., Harries A., and Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health 10 (2005) 734-742
49. Maher D., and Raviglione M. Global epidemiology of tuberculosis. Clin Chest Med 26 (2005) 167-182 v
50. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA 98 (2001) 5752-5757
51. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., and Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 (2005) 47-52
52. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
53. Mustafa A.S., Shaban F.A., Abal A.T., Al-Attiyah R., Wiker H.G., Lundin K.E., et al. Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines. Infect Immun 68 (2000) 3933-3940
54. North R.J., and Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 22 (2004) 599-623
55. Olsen A.W., Hansen P.R., Holm A., and Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30 (2000) 1724-1732
56. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 (2004) 6148-6150
57. Pal P.G., and Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 60 (1992) 4781-4792
58. Portnoy D.A., Tweten R.K., Kehoe M., and Bielecki J. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect Immun 60 (1992) 2710-2717
59. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75 (2007) 4105-4115
60. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 (2006) 4634-4643
61. Skeiky Y.A., Alderson M.R., Ovendale P.J., Lobet Y., Dalemans W., Orme I.M., et al. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine 23 (2005) 3937-3945
62. Skeiky Y.A., Lodes M.J., Guderian J.A., Mohamath R., Bement T., Alderson M.R., et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 67 (1999) 3998-4007
63. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
64. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 70 (2002) 5446-5453
65. Skjot R.L., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68 (2000) 214-220
66. Smith S.M., Klein M.R., Malin A.S., Sillah J., Huygen K., Andersen P., et al. Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia. Infect Immun 68 (2000) 7144-7148
67. Sonnenberg M.G., and Belisle J.T. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 65 (1997) 4515-4524
68. Sterne J.A., Rodrigues L.C., and Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 2 (1998) 200-207
69. Sudre P., ten Dam G., and Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 70 (1992) 149-159
70. Toussirot E., and Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5 (2004) 581-594
71. Tullius M.V., Harth G., Maslesa-Galic S., Dillon B.J., and Horwitz M.A. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76 (2008) 5200-5214
72. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30 (2000) 3689-3698
73. Weinrich-Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 (2001) 2773-2778
74. Weldingh K., Rosenkrands I., Jacobsen S., Rasmussen P.B., Elhay M.J., and Andersen P. Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun 66 (1998) 3492-3500